Life Science Alliance,
Journal Year:
2023,
Volume and Issue:
6(7), P. e202301969 - e202301969
Published: April 11, 2023
A
soluble
ACE2
protein
bioengineered
for
long
duration
of
action
and
high
affinity
to
SARS-CoV-2
was
administered
either
intranasally
(IN)
or
intraperitoneally
(IP)
SARS-CoV-2–inoculated
k18hACE2
mice.
This
decoy
(ACE2
618-DDC-ABD)
given
IN
IP,
pre-
post-inoculation,
IN,
+
IP
but
only
post-inoculation.
Survival
by
day
5
0%
in
untreated
mice,
40%
the
IP-pre,
90%
IN-pre
group.
In
group,
brain
histopathology
essentially
normal
lung
significantly
improved.
Consistent
with
this,
titers
were
undetectable
reduced
When
618-DDC-ABD
survival
30%
20%
We
conclude
that
results
markedly
improved
provides
organ
protection
when
as
compared
systemically
after
viral
inoculation,
lowering
is
a
critical
determinant
protection.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 1, 2025
Rapid
on-site
typing
methods
for
SARS-CoV-2
variants
of
concern
are
crucial
its
effective
surveillance
and
control.
Herein,
a
smart
single-loop-mediated
isothermal
amplification
(ssLAMP)
method
with
the
absence
an
inner
primer
but
addition
swarm
differentiation
Omicron
is
developed.
This
unique
design
strategy
offers
greater
flexibility
in
introducing
single
nucleotide
polymorphism
(SNP)
identification
probes
enables
multiple
detection
assays
including
BA.1,
BA.2,
BA.3,
BA.4,
BA.5.
A
3D-printed
portable
dual
fluorescence
visualization
device
smartphone
app
developed
to
enable
point-of-care
testing.
assay
rapid
(within
90
min),
highly
sensitive
(100
copies/reaction),
specific
(identification
SNP)
SARA-CoV-2
variants.
The
ssLAMP
identifies
five
BA.5-positive
samples
among
97
nasopharyngeal
swab
from
clinic,
100%
concordance
rate
Sanger
sequencing.
system
expected
be
utilized
on-site,
specific,
variants,
great
application
potential
pathogen
genotyping,
early
cancer
screening,
other
areas
SNP
mutation
detection.
iLABMED,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 8, 2025
ABSTRACT
Background
Coronavirus
disease
2019
(COVID‐19),
caused
by
severe
acute
respiratory
syndrome
coronavirus
2
(SARS‐CoV‐2),
continues
to
impose
a
significant
global
health
burden.
Limited
data
exist
regarding
antibody
responses
breakthrough
infections
the
Delta
and
Omicron
variants
of
SARS‐CoV‐2.
This
study
aimed
compare
levels
their
relationships
with
clinical
features
in
patients
infections.
Methods
Sera
from
were
analyzed
for
IgG,
IgM,
IgA,
neutralizing
antibodies
(NAbs)
using
fully
automated
chemiluminescence
immunoassay
analyzer.
Antibody
then
compared
correlated
features.
Results
Booster
COVID‐19
vaccination
was
associated
higher
NAb
IgG
breakthrough‐infected
individuals
(
β
=
0.51,
95%
confidence
interval
[CI]:
0.12–0.90,
0.84,
CI:
0.35–1.33,
respectively).
Individuals
infected
variant
exhibited
IgM
IgA
those
0.80,
0.46–1.14,
0.55,
0.13–0.98,
The
SARS‐CoV‐2
RNA
clearance
time
negatively
(correlation
coefficient
r
s
−0.31
−0.26,
respectively)
−0.29
−0.32,
Conclusions
Patients
than
variant.
Elevated
levels,
booster
vaccination,
shorter
times.
These
findings
underscore
enhanced
immunogenicity
mitigating
duration
viral
positivity.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Sept. 14, 2023
Abstract
Coronavirus
disease
2019
(COVID-19)
was
first
reported
three
years
ago,
when
a
group
of
individuals
were
infected
with
the
original
SARS-CoV-2
strain,
based
on
which
vaccines
developed.
Here,
we
develop
six
human
monoclonal
antibodies
(mAbs)
from
two
elite
convalescents
in
Wuhan
and
show
that
these
mAbs
recognize
diverse
epitopes
receptor
binding
domain
(RBD)
can
inhibit
infection
strain
variants
concern
(VOCs)
to
varying
degrees,
including
Omicron
strains
XBB
XBB.1.5.
Of
mAbs,
most
broadly
potently
neutralizing
(7B3
14B1)
exhibit
prophylactic
activity
against
WT
therapeutic
effects
Delta
variant
challenge
K18-hACE2
KI
mice.
Furthermore,
post-exposure
treatment
7B3
protects
mice
lethal
infection.
Cryo-EM
analysis
spike
trimer
complexed
14B1
or
reveals
bind
partially
overlapped
onto
RBD
spike,
sterically
disrupt
angiotensin-converting
enzyme
2
(hACE2)
RBD.
Our
results
suggest
different
are
present
COVID-19
by
ancestral
indicating
people
benefit
former
infections
despite
extensive
immune
escape
SARS-CoV-2.
Life Science Alliance,
Journal Year:
2023,
Volume and Issue:
6(7), P. e202301969 - e202301969
Published: April 11, 2023
A
soluble
ACE2
protein
bioengineered
for
long
duration
of
action
and
high
affinity
to
SARS-CoV-2
was
administered
either
intranasally
(IN)
or
intraperitoneally
(IP)
SARS-CoV-2–inoculated
k18hACE2
mice.
This
decoy
(ACE2
618-DDC-ABD)
given
IN
IP,
pre-
post-inoculation,
IN,
+
IP
but
only
post-inoculation.
Survival
by
day
5
0%
in
untreated
mice,
40%
the
IP-pre,
90%
IN-pre
group.
In
group,
brain
histopathology
essentially
normal
lung
significantly
improved.
Consistent
with
this,
titers
were
undetectable
reduced
When
618-DDC-ABD
survival
30%
20%
We
conclude
that
results
markedly
improved
provides
organ
protection
when
as
compared
systemically
after
viral
inoculation,
lowering
is
a
critical
determinant
protection.
